Vertex presents new data on benefits of alyftrek® and importance of achieving lower sweat chloride levels at the european cystic fibrosis conference

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with cftr modulators and, in particular, alyftrek® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the united states and united kingdom and is currently under review with health authorities in the eu, canada, australia, new zealand and switzerland. these data were presented at this year's e.
VRTX Ratings Summary
VRTX Quant Ranking